Aclaris Therapeutics Inc
ACRS
1.00USD-0.02 (-1.96%)Delayed as of 07 Dec 2023, 03:05 pmWatchlist
Market Summary
USD1.00-0.02
Delayedas of 07 Dec 2023, 03:05 pm-1.96%
ACRS Stock Price
View Fullscreen
ACRS RSI Chart
ACRS Valuation
ACRS Price/Sales (Trailing)
ACRS Profitability
ACRS Fundamentals
ACRS Revenue
ACRS Earnings
Price Action
52 Week Range
0.9618.54
(Low)(High)
Last 7 days
14.8%
Last 30 days
-81.6%
Last 90 days
-86.7%
Trailing 12 Months
-93.7%
How does ACRS drawdown profile look like?
ACRS Financial Health
ACRS Investor Care
Historical Charts for Stock Metrics
Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
| Year | Q1 | Q2 | Q3 | Q4 |
|---|---|---|---|---|
| 2023 | 30.8M | 31.2M | 21.4M | 0 |
| 2022 | 6.4M | 6.1M | 23.5M | 29.8M |
| 2021 | 6.9M | 6.6M | 6.8M | 6.8M |
| 2020 | 4.4M | 5.5M | 6.0M | 6.5M |
| 2019 | 9.7M | 6.9M | 6.8M | 4.2M |
| 2018 | 4.1M | 6.5M | 6.9M | 9.6M |
| 2017 | 0 | 0 | 0 | 1.7M |
| 2016 | 0 | 0 | 0 | 0 |
| 2015 | 38.0K | 60.0K | 82.0K | 104.0K |
| 2014 | 19.8K | 18.5K | 17.3K | 16.0K |
| 2013 | 0 | 0 | 0 | 21.0K |
Get all data in R, Python etc through our Historical Stock Data APIs
Latest Insider Trading transactions for ACRS
Filter Transactions| Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
|---|---|---|---|---|---|---|
| Oct 23, 2023 | monahan joseph | sold | -30,460 | 5.0767 | -6,000 | chief scientific officer |
| Sep 06, 2023 | balthaser kevin | bought | 74,971 | 7.9 | 9,490 | chief financial officer |
| Sep 01, 2023 | balthaser kevin | acquired | - | - | 1,000 | chief financial officer |
| Sep 01, 2023 | balthaser kevin | sold (taxes) | -2,251 | 7.9 | -285 | chief financial officer |
| Aug 28, 2023 | loerop james | bought | 99,958 | 6.7976 | 14,705 | chief business officer |
| Aug 21, 2023 | monahan joseph | sold | -43,894 | 7.3158 | -6,000 | chief scientific officer |
| Aug 01, 2023 | manion douglas j. | sold (taxes) | -43,527 | 9.81 | -4,437 | pres and ceo |
| Aug 01, 2023 | manion douglas j. | acquired | - | - | 15,575 | pres and ceo |
| Jul 01, 2023 | cawkwell gail | sold (taxes) | -56,070 | 10.37 | -5,407 | chief medical officer |
| Jul 01, 2023 | cawkwell gail | acquired | - | - | 15,000 | chief medical officer |
Which funds bought or sold ACRS recently?
View All Details| Datesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
|---|---|---|---|---|---|---|
| Nov 24, 2023 | DEUTSCHE BANK AG\ | reduced | -85.8 | -10,211,200 | 1,057,020 | -% |
| Nov 21, 2023 | Walleye Capital LLC | reduced | -66.05 | -2,747,840 | 794,340 | -% |
| Nov 21, 2023 | Walleye Trading LLC | reduced | -29.36 | -256,252 | 224,159 | -% |
| Nov 17, 2023 | JACOBS LEVY EQUITY MANAGEMENT, INC | added | 241 | 669,556 | 1,202,040 | 0.01% |
| Nov 15, 2023 | MORGAN STANLEY | added | 3.89 | -5,319,050 | 11,634,000 | -% |
| Nov 15, 2023 | GSA CAPITAL PARTNERS LLP | reduced | -54.51 | -605,000 | 260,000 | 0.02% |
| Nov 15, 2023 | Tudor Investment Corp Et Al | added | - | -116,793 | 227,304 | -% |
| Nov 15, 2023 | JANE STREET GROUP, LLC | added | 8.62 | -442,422 | 1,123,810 | -% |
| Nov 15, 2023 | Baker Avenue Asset Management, LP | new | - | 233 | 233 | -% |
| Nov 15, 2023 | MANUFACTURERS LIFE INSURANCE COMPANY, THE | added | 1.85 | -93,211 | 191,622 | -% |
Latest Funds Activity
Calls
Puts
Net Call Options
No. of Funds
Schedule 13G FIlings of Aclaris Therapeutics Inc
| Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
|---|---|---|---|---|---|
| Nov 24, 2023 | tang capital partners lp | 6.1% | 4,338,155 | SC 13G | |
| Sep 05, 2023 | citadel advisors llc | 4.7% | 6 | SC 13G | |
| Apr 10, 2023 | wellington management group llp | 11.05% | 7,372,601 | SC 13G/A | |
| Mar 16, 2023 | biotechnology value fund l p | 2.7% | 1,794,881 | SC 13G | |
| Feb 14, 2023 | rock springs capital management lp | 5.94% | 3,961,249 | SC 13G/A | |
| Feb 14, 2023 | biotechnology value fund l p | 2.6% | 1,732,725 | SC 13G/A | |
| Feb 13, 2023 | foresite capital fund iv, l.p. | 4.2% | 2,808,034 | SC 13G/A | |
| Feb 06, 2023 | wellington management group llp | 8.22% | 5,484,013 | SC 13G/A | |
| Jan 31, 2023 | blackrock inc. | 7.6% | 5,087,435 | SC 13G/A | |
| Apr 25, 2022 | ra capital management, l.p. | 7.1% | 4,398,453 | SC 13G |
Recent SEC filings of Aclaris Therapeutics Inc
View All Filings| Date Filed | Form Type | Document | |
|---|---|---|---|
| Nov 24, 2023 | SC 13G | Major Ownership Report | |
| Nov 13, 2023 | 8-K | Current Report | |
| Nov 06, 2023 | 8-K | Current Report | |
| Nov 06, 2023 | 10-Q | Quarterly Report | |
| Oct 25, 2023 | 4 | Insider Trading | |
| Oct 23, 2023 | 144 | Notice of Insider Sale Intent | |
| Sep 18, 2023 | 8-K | Current Report | |
| Sep 07, 2023 | 4 | Insider Trading | |
| Sep 05, 2023 | SC 13G | Major Ownership Report | |
| Sep 05, 2023 | 4 | Insider Trading |
Peers (Alternatives to Aclaris Therapeutics Inc)
View All Peers In Detail| Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
|---|---|---|---|---|---|---|---|---|
| LARGE-CAP | ||||||||
DHR | 163.2B | 29.6B | 12.94% | -16.78% | 27.58 | 5.52 | -5.39% | -12.54% |
IDXX | 43.3B | 3.6B | 23.29% | 25.56% | 52.66 | 12.08 | 7.43% | 22.86% |
A | 37.8B | 7.0B | 20.00% | -14.74% | 33.37 | 5.41 | 5.03% | -14.68% |
DGX | 15.1B | 9.3B | 0.81% | -9.39% | 19.81 | 1.63 | -9.69% | -38.22% |
EXAS | 11.8B | 2.4B | -0.06% | 41.10% | -41.76 | 4.9 | 19.99% | 60.62% |
| MID-CAP | ||||||||
CRL | 10.3B | 4.2B | 10.65% | -4.98% | 21.68 | 2.44 | 11.49% | 8.84% |
MEDP | 8.5B | 1.8B | 3.40% | 36.73% | 31.26 | 4.79 | 29.62% | 20.49% |
NTRA | 6.9B | 988.7M | 34.39% | 49.28% | -13.8 | 6.97 | 27.41% | 8.51% |
NEOG | 3.9B | 919.1M | 13.84% | 16.34% | -146.51 | 4.24 | 73.02% | -172.93% |
GH | 3.0B | 535.8M | -7.21% | -48.01% | -7.02 | 5.66 | 24.38% | 26.34% |
| SMALL-CAP | ||||||||
CDNA | 522.0M | 297.1M | 48.77% | -26.91% | -5.77 | 1.76 | -6.74% | -21.60% |
ACRS | 72.2M | 21.4M | -81.57% | -93.66% | -0.63 | 3.37 | -8.80% | -39.66% |
AWH | 28.4M | 9.2M | -30.15% | -40.72% | -1.61 | 3.09 | 16.43% | 48.38% |
APDN | 14.3M | 16.1M | 27.59% | -22.38% | -2.03 | 0.89 | -8.51% | 41.77% |
BIOC | 144.4K | - | -82.76% | -93.43% | 0 | 0.76 | -57.78% | -93.13% |
Aclaris Therapeutics Inc News
Latest updates
Financials for Aclaris Therapeutics Inc
Income Statement (Last 12 Months)
| Income Statement (Quarterly) | ||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Description | (%) Q/Q | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 | 2018Q3 |
| Revenue | 396.6% | 9,282,000 | 1,869,000 | 2,528,000 | 7,753,000 | 19,018,000 | 1,528,000 | 1,453,000 | 1,501,000 | 1,659,000 | 1,824,000 | 1,777,000 | 1,580,000 | 1,449,000 | 2,046,000 | 1,407,000 | 1,095,000 | 983,000 | 886,000 | 1,263,000 | 3,669,000 | 1,118,000 |
| Cost Of Revenue | -18.6% | 848,000 | 1,042,000 | 808,000 | 877,000 | 923,000 | 1,068,000 | 1,155,000 | 1,149,000 | 1,099,000 | 1,263,000 | 1,202,000 | 1,286,000 | 1,189,000 | 1,389,000 | 1,269,000 | 1,027,500 | 826,000 | 994,000 | 1,207,000 | 1,190,000 | 1,067,000 |
| Gross Profit | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 160,000 | 435,000 |
| Costs and Expenses | 21.3% | 40,859,000 | 33,684,000 | 32,446,000 | 36,832,000 | 39,892,000 | 22,522,000 | 20,360,000 | 24,394,000 | 21,954,000 | 19,830,000 | 30,306,000 | 15,140,000 | 11,914,000 | 13,427,000 | 16,913,000 | 13,058,000 | 23,847,000 | 55,656,000 | 28,314,000 | 13,283,500 | 22,460,000 |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 39,198,000 | 33,885,000 |
| S&GA Expenses | -14.7% | 7,091,000 | 8,317,000 | 8,790,000 | 7,146,000 | 5,813,000 | 6,075,000 | 6,099,000 | 6,943,000 | 5,979,000 | 5,870,000 | 4,827,000 | 4,898,500 | 3,859,000 | 5,572,000 | 6,200,000 | 6,056,000 | 6,838,000 | 7,469,000 | 7,464,000 | 13,884,500 | 63,000 |
| R&D Expenses | -5.5% | 23,876,000 | 25,275,000 | 22,587,000 | 21,072,000 | 23,656,000 | 18,779,000 | 14,306,000 | 14,102,000 | 13,976,000 | 7,897,000 | 7,838,000 | 8,955,500 | 6,240,000 | 6,466,000 | 7,677,000 | 10,825,500 | 16,183,000 | 17,519,000 | 19,643,000 | 18,710,500 | 15,189,000 |
| EBITDA Margin | - | - | - | -2.79 | -2.89 | - | -14.67 | -13.99 | -13.30 | - | - | -7.34 | -7.72 | -18.58 | -19.96 | -11.63 | -25.34 | -10.67 | -10.65 | - | - | - |
| EBT Margin | - | - | - | -2.82 | -2.92 | - | -14.80 | -14.12 | -13.44 | - | - | -7.49 | -7.92 | -18.93 | -20.53 | -12.14 | -26.86 | -11.27 | -11.14 | - | - | - |
| Net Income | 1.0% | -29,261,000 | -29,569,000 | -28,160,000 | -27,635,000 | -19,952,000 | -20,532,000 | -18,789,000 | -22,804,000 | -21,146,000 | -18,161,000 | -28,754,000 | -13,173,000 | -10,659,000 | -11,597,000 | -15,586,000 | -18,594,000 | -55,319,000 | -49,876,000 | -37,565,000 | -38,551,000 | -32,740,000 |
| Net Income Margin | 100.0% | - | -3.38 | -3.12 | -2.92 | -3.49 | -13.56 | -12.57 | -13.44 | -11.88 | -10.67 | -9.37 | -7.87 | -9.41 | -18.28 | -14.91 | -38.17 | - | - | - | - | - |
| Free Cashflow | 100.0% | - | -20,885,000 | -26,906,000 | -19,220,000 | -7,967,000 | -19,852,000 | -21,133,000 | -17,275,000 | -10,662,000 | -12,247,000 | -12,240,000 | -8,865,000 | -12,454,000 | -10,838,000 | -6,929,000 | -20,656,000 | - | - | - | - | - |
Balance Sheet(In Millions)
| Balance Sheet | (In Millions) | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Description | (%) Q/Q | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 | 2018Q3 |
| Assets | -7.3% | 218 | 236 | 230 | 255 | 268 | 278 | 227 | 251 | 263 | 288 | 161 | 71.00 | 72.00 | 85.00 | 97.00 | 98.00 | 160 | 217 | 253 | 276 | 176 |
| Current Assets | -7.4% | 123 | 133 | 184 | 232 | 257 | 259 | 191 | 205 | 206 | 241 | 135 | 57.00 | 58.00 | 71.00 | 83.00 | 84.00 | 145 | 138 | 157 | 179 | 146 |
| Cash Equivalents | 25.3% | 39.00 | 31.00 | 45.00 | 45.00 | 62.00 | 68.00 | 36.00 | 27.00 | 54.00 | 113 | 35.00 | 22.00 | 25.00 | 33.00 | 54.00 | 36.00 | 30.00 | 32.00 | 34.00 | 57.00 | 27.00 |
| Inventory | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0.00 | 0.00 | 1.00 | 1.00 | 1.00 |
| Net PPE | -7.1% | 2.00 | 2.00 | 2.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 2.00 | 2.00 | 2.00 | 2.00 | 2.00 | 3.00 | 4.00 | 4.00 | 2.00 | 4.00 |
| Goodwill | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 19.00 | - | - | 19.00 | 19.00 | 19.00 |
| Liabilities | 11.0% | 62.00 | 56.00 | 53.00 | 57.00 | 48.00 | 42.00 | 46.00 | 54.00 | 47.00 | 54.00 | 49.00 | 33.00 | 31.00 | 36.00 | 39.00 | 28.00 | 75.00 | 80.00 | 71.00 | 60.00 | 30.00 |
| Current Liabilities | 19.7% | 27.00 | 23.00 | 18.00 | 22.00 | 20.00 | 16.00 | 17.00 | 23.00 | 18.00 | 15.00 | 15.00 | 15.00 | 13.00 | 18.00 | 21.00 | 22.00 | 39.00 | 43.00 | 36.00 | 27.00 | 22.00 |
| Long Term Debt | - | - | - | - | - | - | - | - | - | - | 11.00 | 11.00 | 11.00 | 11.00 | 11.00 | 11.00 | - | 30.00 | 30.00 | 30.00 | 30.00 | - |
| Shareholder's Equity | -13.0% | 156 | 180 | 177 | 198 | 220 | 236 | 180 | 197 | 217 | 234 | 112 | 38.00 | 41.00 | 49.00 | 58.00 | 70.00 | 85.00 | 137 | 182 | 215 | 146 |
| Retained Earnings | -4.0% | -769 | -740 | -710 | -682 | -654 | -634 | -614 | -595 | -572 | -551 | -533 | -504 | -491 | -480 | -469 | -453 | -434 | -379 | -329 | -292 | -253 |
| Additional Paid-In Capital | 0.6% | 927 | 921 | 888 | 881 | 876 | 872 | 795 | 793 | 789 | 785 | 646 | 542 | 532 | 530 | 527 | 524 | 520 | 517 | 512 | 507 | 400 |
| Shares Outstanding | 0.1% | 71.00 | 71.00 | 67.00 | 67.00 | 67.00 | 66.00 | 61.00 | 61.00 | 61.00 | 54.00 | 50.00 | 45.00 | 42.00 | 42.00 | 42.00 | 41.00 | 41.00 | 41.00 | 41.00 | 33.00 | 31.00 |
Cashflow (Last 12 Months)(In Thousands)
| Cashflow (Quarterly) | ||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Description | (%) Q/Q | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 | 2018Q3 |
| Cashflow From Operations | -18.9% | -24,557,000 | -20,654,000 | -26,353,000 | -19,115,000 | -7,817,000 | -19,666,000 | -20,969,000 | -17,075,000 | -10,606,000 | -12,221,000 | -12,232,000 | -8,857,000 | -12,150,000 | -10,821,000 | -6,805,000 | -20,390,000 | -23,359,000 | -21,378,000 | -31,318,000 | -27,248,000 | -29,858,000 |
| Share Based Compensation | -8.8% | 5,948,000 | 6,522,000 | 6,806,000 | 4,813,000 | 4,188,000 | 3,692,000 | 2,346,000 | 3,851,000 | 3,702,000 | 3,832,000 | 2,675,000 | 2,504,000 | 1,941,000 | 3,309,000 | 3,453,000 | 3,181,000 | 3,320,000 | 4,814,000 | 4,862,000 | 4,956,000 | 4,707,000 |
| Cashflow From Investing | 265.5% | 32,534,000 | -19,662,000 | 25,798,000 | 2,702,000 | 1,217,000 | -21,223,000 | 29,932,000 | -9,176,000 | -37,672,000 | -45,470,000 | -75,314,000 | -2,305,000 | 5,237,000 | -10,487,000 | 13,942,000 | 56,438,000 | 21,673,000 | 18,952,000 | 8,616,000 | -70,506,000 | 10,394,000 |
| Cashflow From Financing | -Infinity% | -87,000 | - | - | 37,000 | -11,000 | 72,811,000 | 30,000 | -2,000 | -11,567,000 | 135,871,000 | 100,750,000 | 7,829,000 | -278,000 | -97,000 | 10,918,000 | -30,009,000 | -70,000 | -117,000 | -120,000 | 128,183,000 | 19,000 |
ACRS Income Statement
2023-09-30CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($) $ in Thousands | 3 Months Ended | 9 Months Ended | ||
|---|---|---|---|---|
Sep. 30, 2023 | Sep. 30, 2022 | Sep. 30, 2023 | Sep. 30, 2022 | |
| Revenues: | ||||
| Total revenue | $ 9,282 | $ 19,018 | $ 13,679 | $ 21,999 |
| Costs and expenses: | ||||
| Cost of revenue | 848 | 923 | 2,698 | 3,146 |
| Research and development | 23,876 | 23,656 | 71,738 | 56,741 |
| General and administrative | 7,091 | 5,813 | 24,198 | 17,987 |
| Licensing | 7,344 | 7,300 | 8,955 | 7,300 |
| Revaluation of contingent consideration | 1,700 | 2,200 | (600) | (2,400) |
| Total costs and expenses | 40,859 | 39,892 | 106,989 | 82,774 |
| Loss from operations | (31,577) | (20,874) | (93,310) | (60,775) |
| Other income, net | 2,316 | 922 | 6,320 | 1,502 |
| Net loss | $ (29,261) | $ (19,952) | $ (86,990) | $ (59,273) |
| Net loss per share, basic | $ (0.41) | $ (0.30) | $ (1.25) | $ (0.92) |
| Net loss per share, diluted | $ (0.41) | $ (0.30) | $ (1.25) | $ (0.92) |
| Weighted average common shares outstanding, basic | 70,807,934 | 66,675,337 | 69,452,495 | 64,718,008 |
| Weighted average common shares outstanding, diluted | 70,807,934 | 66,675,337 | 69,452,495 | 64,718,008 |
| Other comprehensive loss: | ||||
| Unrealized loss on marketable securities, net of tax of $0 | $ (18) | $ (139) | $ (232) | $ (1,241) |
| Total other comprehensive loss | (18) | (139) | (232) | (1,241) |
| Comprehensive loss | (29,279) | (20,091) | (87,222) | (60,514) |
| Contract research | ||||
| Revenues: | ||||
| Total revenue | 705 | 1,090 | 2,469 | 3,529 |
| Licensing | ||||
| Revenues: | ||||
| Total revenue | $ 8,577 | 17,898 | $ 11,210 | 18,378 |
| Other | ||||
| Revenues: | ||||
| Total revenue | $ 30 | $ 92 | ||
ACRS Balance Sheet
2023-09-30CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands | Sep. 30, 2023 | Dec. 31, 2022 |
|---|---|---|
| Current assets: | ||
| Cash and cash equivalents | $ 39,040 | $ 45,277 |
| Short-term marketable securities | 64,012 | 172,294 |
| Accounts receivable, net | 346 | 484 |
| Prepaid expenses and other current assets | 19,670 | 13,495 |
| Total current assets | 123,068 | 231,550 |
| Marketable securities | 83,944 | 12,242 |
| Property and equipment, net | 1,764 | 1,099 |
| Intangible assets | 6,917 | 6,973 |
| Other assets | 2,661 | 2,732 |
| Total Assets | 218,354 | 254,596 |
| Current liabilities: | ||
| Accounts payable | 9,648 | 10,351 |
| Accrued expenses | 15,160 | 8,701 |
| Current portion of lease liabilities | 310 | 684 |
| Discontinued operations | 2,202 | 2,202 |
| Total current liabilities | 27,320 | 21,938 |
| Other liabilities | 1,834 | 1,570 |
| Contingent consideration | 32,500 | 33,100 |
| Deferred tax liability | 367 | 367 |
| Total liabilities | 62,021 | 56,975 |
| Commitments and contingencies (Note 14) | ||
| Stockholders' Equity: | ||
| Preferred stock, $0.00001 par value; 10,000,000 shares authorized and no shares issued or outstanding at September 30, 2023 and December 31, 2022 | ||
| Common stock, $0.00001 par value; 200,000,000 and 100,000,000 shares authorized at September 30, 2023 and December 31, 2022, respectively; 70,818,954 and 66,688,647 shares issued and outstanding at September 30, 2023 and December 31, 2022, respectively | 1 | 1 |
| Additional paid-in capital | 926,766 | 880,832 |
| Accumulated other comprehensive loss | (1,129) | (897) |
| Accumulated deficit | (769,305) | (682,315) |
| Total stockholders' equity | 156,333 | 197,621 |
| Total liabilities and stockholders' equity | $ 218,354 | $ 254,596 |
| CEO | Dr. Douglas J. Manion Frcp(C), M.D. |
|---|---|
| WEBSITE | www.aclaristx.com |
| EMPLOYEES | 100 |